Linear Clinical Research Revenue and Competitors
Estimated Revenue & Valuation
- Linear Clinical Research's estimated annual revenue is currently $24.3M per year.
- Linear Clinical Research's estimated revenue per employee is $112,200
Employee Data
- Linear Clinical Research has 217 Employees.
- Linear Clinical Research grew their employee count by 6% last year.
Linear Clinical Research's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head Systems Compliance | Reveal Email/Phone |
3 | Head Project Delivery - Early Phase | Reveal Email/Phone |
4 | Head Quality Assurance | Reveal Email/Phone |
5 | Head Business Development | Reveal Email/Phone |
6 | Recruitment Officer | Reveal Email/Phone |
7 | Facilities Officer | Reveal Email/Phone |
8 | Head Corporate Operations | Reveal Email/Phone |
9 | Director Cancer Trials | Reveal Email/Phone |
10 | Associate Medical Director | Reveal Email/Phone |
Linear Clinical Research Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $119.4M | 659 | N/A | N/A | N/A |
What Is Linear Clinical Research?
As a world class leader, Linear Clinical Research (Linear) is a purpose built state-of-the-art, clinical trials facility operating out of QEII Medical Centre in Perth, Western Australia. Conceived as a focal point for Australian clinical and medical research, Linear is making innovative therapies available to our local community. At Linear the focus is on its phase I facility to support first in human through to phase II clinical trials, including oncology studies. Linear have extensive experience in conducting both healthy volunteer and patient phase I trials, including adaptive healthy volunteer and patient protocol designs. Linear has a variety of departments that specialise in running the clinical trial from business development, start up, recruitment and screening, project teams, quality assurance and laboratory. Each department works together to ensure clinical trials are run safely and efficiently. Reliable clinical trial data is one thing, but at Linear we go further. We actively listen, contribute ideas and add value at every stage of your medical mission, so you can realise your therapy's medical and commercial potential sooner. Located in Australia, where Australia offers a fast regulatory framework to move into human trials without requiring an investigational new drug, Linear is constantly developing capabilities and services to meet the ever-changing demands of our customers. Our vision is to be the first choice for patient empowered trials globally and recognised for innovation and excellence. We are passionate about what they do and set the benchmark for excellence and embrace our One Linear values of: Excellence Respect Integrity Collaboration
keywords:Biotechnology,Healthcare,Medical Diagnostics,PharmaceuticalsN/A
Total Funding
217
Number of Employees
$24.3M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Linear Clinical Research News
Includes Multiple Studies Demonstrating that Post-Translational ... It is consistent with the results of our clinical studies showing that...
Lead investigator Melinda Magyari, MD, PhD, clinical research professor, University of Copenhagen, and colleagues used weighted general linear...
This randomised clinical trial in a hospital setting evaluated the ... We used linear regression and non-linear regression to analyze the...
The researchers recently reported their findings in a new paper in Cell ... circular, even though it shares the same genetic sequence as linear RNA. ... Mona Batish, assistant professor of medical and molecular sciences, UD's ...
Designed by Array Architects, the facility features two linear accelerators ... precision medicine, clinical trials, clinical research, and enhanced ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15M | 218 | 19% | N/A |
#2 | $29.4M | 223 | 54% | N/A |
#3 | $60.6M | 225 | 19% | N/A |
#4 | $37.5M | 235 | 46% | N/A |
#5 | $75.3M | 236 | 13% | N/A |